Comparisons Between Frontline Therapy and a Combination of Eltrombopag Plus Immunosuppression Therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Systematic Review
Background and Aims: This study aimed at comparing the efficacy and safety of eltrombopag (EPAG) plus immunosuppressive therapies (ISTs) and haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the frontline treatment for severe aplastic anemia (SAA) patients.Methods: Four electron...
Main Authors: | Yuan Yang, Jiang Ji, Zengwei Tang, Bing Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.614965/full |
Similar Items
-
Eltrombopag for the treatment of aplastic anemia: current perspectives
by: Lum SH, et al.
Published: (2016-09-01) -
Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant
by: Lan-Ping Xu, et al.
Published: (2017-01-01) -
Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China
by: Wei Zuo, et al.
Published: (2020-11-01) -
Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study
by: Lan-Ping Xu, et al.
Published: (2019-09-01) -
Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia
by: Lixin Xu, et al.
Published: (2018-03-01)